
Labcorp
LH · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $30,1 bn
- Div. yield
- 1,4%
- Year to date
- +47,7%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
3 ✓ · 4 — · 2 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 30,0 | 25,3 | 25,1 |
| Forward P/E | 18,6 | — | 16,2 |
| PEG | 3,2 | — | 2,2 |
| P/S | 2,1 | 1,6 | 2,2 |
| EV/EBITDA | 19,8 | 17,9 | 17,3 |
| P/FCF | 23,4 | — | 19,5 |
| P/B | 3,4 | 2,4 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 27 analysts
- Buy
- 21
- Hold
- 6
- Sell
- 0
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 4,80 | 4,78 | Down −0,3% |
| Q2 2026 | 4,92 | 4,99 | Up +1,4% |
| Q1 2026 | 4,21 | 4,25 | Up +1,0% |
| Q4 2025 | 4,06 | 4,07 | Up +0,3% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,81 bn | 3,73 bn | 3,54 bn | 3,52 bn | 3,56 bn | 3,53 bn | 3,35 bn | 3,33 bn | 3,28 bn | 3,22 bn | 3,18 bn | 3,03 bn |
| EPS | 3,22 | 3,64 | 3,35 | 1,98 | 3,12 | 2,84 | 2,52 | 1,71 | 2,00 | 2,43 | 2,69 | −1,86 |
| Margin | 6,9% | 8,0% | 7,9% | 4,7% | 7,3% | 6,7% | 6,4% | 4,3% | 5,2% | 6,4% | 7,2% | −5,5% |
| FCF | 412 m | 314 m | 70,5 m | 490 m | 281 m | 543 m | −108 m | 665 m | 162 m | 433 m | −164 m | 412 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $11,7 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| caveney brian j10 Nov 2026 · sale | $744 080 | 2 000 | $372,04 |
| vaughn bryan t3 Nov 2026 · sale | $108 232 | 306 | $353,70 |
| parham richelle p30 Oct 2026 · sale | $389 395 | 1 078 | $361,22 |
| anderson kerrii b17 Aug 2026 · sale | $954 060 | 3 000 | $318,02 |
| schechter adam h11 Aug 2026 · sale | $1,50 m | 4 669 | $320,37 |
| summy amy b.4 Aug 2026 · sale | $283 428 | 924 | $306,74 |
| wilkinson peter j3 Aug 2026 · sale | $413 751 | 1 338 | $309,23 |
| wilkinson peter j3 Aug 2026 · sale | $25 356 | 82 | $309,22 |
| vaughn bryan t2 Jul 2026 · sale | $66 968 | 234 | $286,19 |
| kyle kathryn w2 Jul 2026 · sale | $26 329 | 92 | $286,19 |
| kyle kathryn w8 Jun 2026 · sale | $201 084 | 762 | $263,89 |
| schechter adam h11 May 2026 · sale | $1,50 m | 5 903 | $254,50 |
| meltzer jonathan c27 Mar 2026 · sale | $224 055 | 839 | $267,05 |
| wilkinson peter j27 Mar 2026 · sale | $436 093 | 1 633 | $267,05 |
| schechter adam h3 Mar 2026 · sale | $2,44 m | 8 705 | $279,96 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 24 Apr 1991
- Website
- www.labcorp.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
DXCMDexcom | $81,61 | 89★★★★★★★★★★would consider | 31,4 | +13,0% | 19,4% |
DGXQuest Diagnostics | $262,21 | 61★★★★★★★★would watch | 25,5 | +9,1% | 9,5% |
RMDResMed | $238,19 | 83★★★★★★★★★would consider | 21,3 | +9,0% | 27,8% |
STESteris | $261,91 | 75★★★★★★★★★would consider | 31,9 | +8,1% | 13,4% |
CNCCentene Corporation | $74,77 | 72★★★★★★★★★would consider | 24,2 | +9,7% | 0,7% |
Ratio — a score by our methodology, not an investment recommendation.




